Janux Therapeutics (JANX) Change in Acquisitions & Divestments (2021 - 2026)

Janux Therapeutics (JANX) has 6 years of Change in Acquisitions & Divestments data on file, last reported at $121.3 million in Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $121.3 million, up 287.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $495.3 million (up 176.43% YoY), and the FY2025 annual result was $405.3 million, up 90.35% from the prior year.
• Change in Acquisitions & Divestments declined to $121.3 million in Q1 2026 per JANX's latest filing, from $152.9 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $152.9 million in Q4 2025 and troughed at $31.3 million in Q1 2025.
• A 5-year average of $81.0 million and a median of $77.1 million in 2022 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2022 and 2024: Change in Acquisitions & Divestments soared 427.21% in 2022, then slumped 52.89% in 2024.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $86.5 million in 2022, then sank by 48.27% to $44.8 million in 2023, then climbed by 29.61% to $58.0 million in 2024, then soared by 163.67% to $152.9 million in 2025, then fell by 20.67% to $121.3 million in 2026.
• Business Quant data shows JANX's Change in Acquisitions & Divestments at $121.3 million in Q1 2026, $152.9 million in Q4 2025, and $126.4 million in Q3 2025.